Results 21 to 30 of about 36,146 (282)

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

open access: yes, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T.   +9 more
core   +2 more sources

The chronic care for age-related macular degeneration study (CHARMED): Study protocol for a randomized controlled trial

open access: yesTrials, 2011
Background Neovascular age-related macular degeneration is the leading cause of irreversible blindness in people 50 years of age or older in the developed world.
Held Ulrike   +4 more
doaj   +1 more source

Distinguishing wet from dry age-related macular degeneration using three-dimensional computer-automated threshold Amsler grid testing [PDF]

open access: yes, 2011
Background/aims: With the increased efficacy of current therapy for wet age-related macular degeneration (AMD), better ways to detect wet AMD are needed.
Bababeygy, Simon R.   +5 more
core   +1 more source

Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration [PDF]

open access: yes, 2016
Purpose To define a minimum set of outcome measures for tracking, comparing, and improving macular degeneration care. Design Recommendations from a working group of international experts in macular degeneration outcomes registry development and patient ...
Barthelmes, D. (Daniel)   +19 more
core   +4 more sources

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

open access: yes, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto   +5 more
core   +1 more source

Unusual visual loss in a patient with exudative macular degeneration

open access: yesAmerican Journal of Ophthalmology Case Reports, 2022
Purpose: To describe a case of marked vision loss in a patient with neovascular age-related macular degeneration after choroidal neovascular membrane (CNV) improvement and stabilization.
Enoch T. Peng, Sean D. Adrean
doaj   +1 more source

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. [PDF]

open access: yes, 2020
AimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.MethodsThis was a retrospective case-control study of a ...
Amador-Patarroyo, Manuel J   +6 more
core  

Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular Degeneration. [PDF]

open access: yes, 2019
Age-related macular degeneration (AMD) - the leading cause of vision loss in the elderly - share many risks factors as atherosclerosis, which exhibits loss of vascular compliance resulting from aging and oxidative stress.
Agrawal, Rupesh   +8 more
core   +2 more sources

Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation

open access: yesEBioMedicine, 2018
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in developed countries. Neovascular AMD (nAMD) accounts for 90% of AMD-related vision loss.
Karis Little   +4 more
doaj   +1 more source

Comparative Real-World Efficacy of Anti-Vascular Endothelial Growth Factor Agents in Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Study.

open access: hybridOphthalmologica
Berco E   +8 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy